Orbactiv (Oritavancin Diphosphate) Patent Expiration, LOE Window & CMS Spending

Orbactiv (Oritavancin Diphosphate) by Melinta Therapeutics: FDA Orange Book LOE 2035-07-16, 0 AB generics, $1.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMelinta Therapeutics
FDA Application & PathwayN206334 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-07-16
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.5M
2024 Medicare Part D Spend$280K
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel